公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2022 | Afatinib for the Treatment of Non-Small Cell Lung Cancer Harboring Uncommon EGFR Mutations: An Updated Database of 1023 Cases Brief Report | CHIH-HSIN YANG ; Schuler, Martin; Popat, Sanjay; Miura, Satoru; Park, Keunchil; Passaro, Antonio; De Marinis, Filippo; Solca, Flavio; Märten, Angela; Kim, Edward S | Frontiers in oncology | 24 | 20 | |
2023 | Brigatinib Versus Alectinib in ALK-Positive NSCLC After Disease Progression on Crizotinib: Results of Phase 3 ALTA-3 Trial | CHIH-HSIN YANG ; Liu, Geoffrey; Lu, Shun; He, Jianxing; Burotto, Mauricio; Ahn, Myung-Ju; Kim, Dong-Wan; Liu, XiaoQing; Zhao, Yanqiu; Vincent, Sylvie; Yin, Jiani; Ma, Xin; Lin, Huamao M; Popat, Sanjay | Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer | 7 | 0 | |
2023 | Correction to: Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies | Popat, Sanjay; Ahn, Myung-Ju; Ekman, Simon; Leighl, Natasha B; Ramalingam, Suresh S; Reungwetwattana, Thanyanan; Siva, Shankar; Tsuboi, Masahiro; Wu, Yi-Long; CHIH-HSIN YANG | Targeted oncology | 0 | 0 | |
2022 | Efficacy and Safety of Brigatinib Compared With Crizotinib in Asian vs. Non-Asian Patients With Locally Advanced or Metastatic ALK-Inhibitor-Naive ALK+ Non-Small Cell Lung Cancer: Final Results From the Phase III ALTA-1L Study | Ahn, Myung J; Kim, Hye R; CHIH-HSIN YANG ; Han, Ji-Yu; Li, Jacky Yu-Chung; Hochmair, Maximilian J; Chang, Gee-Chen; Delmonte, Angelo; Lee, Ki H; Campelo, Rosario G; Gridelli, Cesare; Spira, Alexander I; Califano, Raffaele; Griesinger, Frank; Ghosh, Sharmistha; Felip, Enriqueta; Kim, Dong-Wan; Liu, Yuyin; Zhang, Pingkuan; Popat, Sanjay; Camidge, D Ross | Clinical lung cancer | 5 | 4 | |
2023 | Osimertinib for EGFR-Mutant Non-Small-Cell Lung Cancer Central Nervous System Metastases: Current Evidence and Future Perspectives on Therapeutic Strategies | Popat, Sanjay; Ahn, Myung-Ju; Ekman, Simon; Leighl, Natasha B; Ramalingam, Suresh S; Reungwetwattana, Thanyanan; Siva, Shankar; Tsuboi, Masahiro; Wu, Yi-Long; CHIH-HSIN YANG | Targeted oncology | 5 | 5 | |
2022 | Sequential Afatinib and Osimertinib in Asian Patients with EGFR Mutation-Positive Non-Small Cell Lung Cancer and Acquired T790M: Combined Analysis of Two Global Non-Interventional Studies | Miura, Satoru; Jung, Hyun Ae; Lee, Shin Yup; Lee, Seung Hyeun; Lee, Min Ki; Lee, Yong Chul; Hochmair, Maximilian J; Yang, Cheng-Ta; Märten, Angela; CHIH-HSIN YANG ; Popat, Sanjay | OncoTargets and therapy | 6 | 5 | |
2015 | TIGER-3: A phase 3, open-label, randomized study of rociletinib vs cytotoxic chemotherapy in patients (pts) with mutant EGFR non-small cell lung cancer (NSCLC) progressing on prior EGFR TKI therapy and doublet chemotherapy. | Yang, James Chih-Hsin; Popat, Sanjay; Georgiou, Panos; Miyamoto, Emiko; Isaacson, Jeffrey D.; Wakelee, Heather A. | J. Clin. Oncol. | | | |